Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

IMPORTANCE: The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for BRAF V600 mutations and have been previously shown to be responsive to treatment with vemurafenib, an inhibitor of the BRAF V600 kinase. However, the long-term efficacy...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Diamond, Eli L., Subbiah, Vivek, Lockhart, A. Craig, Blay, Jean-Yves, Puzanov, Igor, Chau, Ian, Raje, Noopur S., Wolf, Jurgen, Erinjeri, Joseph P., Torrisi, Jean, Lacouture, Mario, Elez, Elena, Martínez-Valle, Ferran, Durham, Benjamin, Arcila, Maria E., Ulaner, Gary, Abdel-Wahab, Omar, Pitcher, Bethany, Makrutzki, Martina, Riehl, Todd, Baselga, José, Hyman, David M.
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2017
Assuntos:
Brief Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844839/
https://ncbi.nlm.nih.gov/pubmed/29188284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5029
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares